依达拉奉联合阿替普酶静脉溶栓治疗老年急性脑梗死患者的效果

Effects of Edaravone combined with Alteplase intravenous thrombolysis in treatment of elderly patients with acute cerebral infarction

目的:观察依达拉奉联合阿替普酶静脉溶栓治疗老年急性脑梗死(ACI)患者的效果。方法:选取2022年8月至2023年8月该院收治的80例老年ACI患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各40例。对照组给予阿替普酶静脉溶栓治疗,研究组在对照组基础上联合依达拉奉治疗,比较两组临床疗效,治疗前后大脑中动脉血流速度[收缩期峰值血流速度(Vs)、舒张末期血流速度(Vd)及平均血流速度(Vm)]、CXC趋化因子配体1(CXCL1)和CC趋化因子配体4(CCL4)水平,以及不良反应发生率。结果:研究组治疗总有效率为95.00%(38/40),高于对照组的80.00%(32/40),差异有统计学意义(P<0.05);治疗后,两组Vs、Vd、Vm等大脑中动脉血流速度均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组CXCL1、CCL4水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:依达拉奉联合阿替普酶静脉溶栓治疗老年ACI患者可提高治疗总有效率和大脑中动脉血流速度,以及降低CXCL1和CCL4水平,效果优于单纯阿替普酶静脉溶栓治疗。

Objective:To observe effects of Edaravone combined with Alteplase intravenous thrombolysis in treatmentt of elderly patients with acute cerebral infarction(ACI).Methods:A prospective study was conducted on 80 patients with ACI admitted to the hospital from August 2022 to August 2023.According to the random number table method,they were divided into study group and control group,40 cases in each group.The control group was treated with Alteplase intravenous thrombolysis,while the study group was treated with Edaravone on the basis of that of the control group.The clinical efficacy,the levels of middle cerebral artery[peak systolic blood flow velocity(Vs),end diastolic blood flow velocity(Vd)and mean blood flow velocity(Vm)],the levels of CXC chemokine ligand 1(CXCL1)and CC chemokine ligand 4(CCL4),and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 95.00%(38/40),which was higher than 80.00%(32/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the blood flow velocities of Vs,Vd,Vm and other middle cerebral arteries in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CXCL1 and CCL4 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Edaravone combined with Alteplase intravenous thrombolysis in the elderly patients with ACI can improve the total effective rate of treatment and the levels of middle cerebral artery blood flow velocity,and reduce the levels of CXCL1 and CCL4.Moreover,it is superior to simple Alteplase treatment.